![](https://event.businessfrance.fr/business-france-at-bio-convention/wp-content/uploads/sites/1378/2024/02/AdobeStock_199783080.jpeg)
KARLA THERAPEUTICS
![](https://event.businessfrance.fr/business-france-at-bio-convention/wp-content/uploads/sites/1378/2024/04/DvJgYkW7SGPZoobGYGMUeZVWBd6eA3deLCaAeLoe1WM.jpg)
Karla is the first immuno-psychiatry company developing precision therapeutics to treat mental disorders (personalized medicine applied to psychiatry). We have a primary focus on schizophrenia and our immuno-centric approach has potential applications across multiple psychiatric diseases.
Our approach stems from 10 years of research made at Queen Mary University of London.
We have evidence showing that our novel target – a protein that we call “imood” – is critically involved in T cell-mediated homeostatic regulation of brain functions.
We have demonstrated the T cell specificity of imood as well as its capabilities to modulate behavior in wt mice.
Circulating imood can be found in (healthy) human plasma and we have data showing that it is dysregulated in plasma, PBMCs and T cells from psychiatric patients.
We are developing anti-imood mAb as the first precision medicine therapeutic in psychiatry.
– Therapeutic areas: Neuropsychiatry, CNS disorders
– Based in: Saint-Beauzire (FRANCE)
– Employees: 1 – 10
– Created in: 2022
![](https://event.businessfrance.fr/business-france-at-bio-convention/wp-content/uploads/sites/1378/2024/04/France-2030-4.png)